

Michael Brines

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9168947/publications.pdf>

Version: 2024-02-01

92
papers

10,215
citations

53794

45
h-index

51608

86
g-index

94
all docs

94
docs citations

94
times ranked

5922
citing authors

#	ARTICLE	IF	CITATIONS
1	Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. <i>Molecular Medicine</i> , 2002, 8, 495-505.	4.4	932
2	Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic. <i>Science</i> , 2004, 305, 239-242.	12.6	775
3	Erythropoietin mediates tissue protection through an erythropoietin and common β -subunit heteroreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14907-14912.	7.1	657
4	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4802-4806.	7.1	556
5	Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis. <i>Journal of Experimental Medicine</i> , 2003, 198, 971-975.	8.5	481
6	Emerging biological roles for erythropoietin in the nervous system. <i>Nature Reviews Neuroscience</i> , 2005, 6, 484-494.	10.2	480
7	Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2258-2263.	7.1	435
8	Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6741-6746.	7.1	416
9	Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10659-10664.	7.1	397
10	Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 9450-9455.	7.1	351
11	Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. <i>Brain Research</i> , 2002, 952, 128-134.	2.2	326
12	Erythropoietin therapy for acute stroke is both safe and beneficial. <i>Molecular Medicine</i> , 2002, 8, 495-505.	4.4	302
13	Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10925-10930.	7.1	280
14	Erythropoietin both protects from and reverses experimental diabetic neuropathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 823-828.	7.1	238
15	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2046-2051.	7.1	231
16	Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5965-5970.	7.1	129
17	Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 552-563.	4.3	128
18	From The Cover: Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16379-16384.	7.1	117

#	ARTICLE	IF	CITATIONS
19	ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. <i>Molecular Medicine</i> , 2014, 20, 658-666.	4.4	115
20	Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1602-1607.	7.1	113
21	The Receptor That Tames the Innate Immune Response. <i>Molecular Medicine</i> , 2012, 18, 486-496.	4.4	111
22	Intervention With an Erythropoietin-Derived Peptide Protects Against Neuroglial and Vascular Degeneration During Diabetic Retinopathy. <i>Diabetes</i> , 2011, 60, 2995-3005.	0.6	105
23	Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006, 172, 27-37.	2.3	103
24	TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 6185-6190.	7.1	100
25	Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go?. <i>Neuroscientist</i> , 2004, 10, 93-98.	3.5	95
26	Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. <i>Diabetologia</i> , 2019, 62, 1478-1487.	6.3	91
27	Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. <i>Molecular Medicine</i> , 2012, 18, 1430-1436.	4.4	89
28	Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 999-1005.	2.5	87
29	Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity. <i>Clinical Cancer Research</i> , 2006, 12, 2607-2612.	7.0	85
30	Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. , 2017, 58, BIO52.		84
31	Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo. <i>Molecular Medicine</i> , 2006, 12, 153-160.	4.4	82
32	Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. <i>Journal of Neurosurgery: Spine</i> , 2006, 4, 310-318.	1.7	82
33	ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density. <i>Molecular Medicine</i> , 2013, 19, 334-345.	4.4	78
34	Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?. <i>Critical Care</i> , 2004, 8, 337.	5.8	75
35	Corneal confocal microscopy: ready for prime time. <i>Australasian journal of optometry, The</i> , 2020, 103, 265-277.	1.3	73
36	Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β_2 -common receptor. <i>Kidney International</i> , 2013, 84, 482-490.	5.2	71

#	ARTICLE	IF	CITATIONS
37	Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. , 2015, 151, 32-40.		71
38	Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Scientific Reports, 2018, 8, 4734.	3.3	70
39	The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors. Blood Purification, 2010, 29, 86-92.	1.8	69
40	Carbamylated Erythropoietin Reduces Radiosurgically-Induced Brain Injury. Molecular Medicine, 2006, 12, 74-80.	4.4	56
41	Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14357-14362.	7.1	51
42	Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17531-17536.	7.1	50
43	A Small Nonerythropoietic Helix B Surface Peptide Based upon Erythropoietin Structure Is Cardioprotective against Ischemic Myocardial Damage. Molecular Medicine, 2011, 17, 194-200.	4.4	50
44	Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3513-3518.	7.1	49
45	Recombinant Human Erythropoietin for Neuroprotection: What Is the Evidence?. Clinical Breast Cancer, 2002, 3, S109-S115.	2.4	48
46	Erythropoietin: not just about erythropoiesis. Lancet, The, 2010, 375, 2142.	13.7	48
47	Cornea nerve fiber quantification and construction of phenotypes in patients with fibromyalgia. Scientific Reports, 2016, 6, 23573.	3.3	48
48	Nonerythropoietic Tissue Protective Compounds Are Highly Effective Facilitators of Wound Healing. Molecular Medicine, 2009, 15, 235-241.	4.4	44
49	ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain. Anesthesiology, 2011, 115, 1084-1092.	2.5	44
50	The mast cell plays a central role in the immune system of teleost fish. Molecular Immunology, 2015, 63, 3-8.	2.2	43
51	Promises and Pitfalls in Erythropoietin-Mediated Tissue Protection. Journal of Investigative Medicine, 2011, 59, 1073-1082.	1.6	40
52	Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?. Heart Failure Reviews, 2008, 13, 415-423.	3.9	38
53	Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Experimental Neurology, 2008, 209, 161-170.	4.1	35
54	Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. Molecular Medicine, 2012, 18, 719-727.	4.4	35

#	ARTICLE	IF	CITATIONS
55	HMGB1 released from nociceptors mediates inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	34
56	ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Investigational Drugs, 2014, 23, 541-550.	4.1	33
57	ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response. Molecular Pain, 2014, 10, 1744-8069-10-13.	2.1	29
58	A Nonerythropoietic Peptide that Mimics the 3D Structure of Erythropoietin Reduces Organ Injury/Dysfunction and Inflammation in Experimental Hemorrhagic Shock. Molecular Medicine, 2011, 17, 883-892.	4.4	27
59	Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. Journal of Molecular Medicine, 2015, 93, 199-210.	3.9	27
60	Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia. Experimental Neurology, 2011, 232, 126-135.	4.1	26
61	Suppression of Coronary Atherosclerosis by Helix B Surface Peptide, a Nonerythropoietic, Tissue-Protective Compound Derived from Erythropoietin. Molecular Medicine, 2013, 19, 195-202.	4.4	25
62	A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation, 2016, 100, 554-562.	1.0	21
63	Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarctionâ€™Dilated Cardiomyopathy. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 446-456.	2.5	20
64	ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitorsâ€™ Angiogenic Potential and Homing Ability. Shock, 2016, 46, 390-397.	2.1	20
65	Discovery of a Master Regulator of Injury and Healing: Tipping the Outcome from Damage toward Repair. Molecular Medicine, 2014, 20, S10-S16.	4.4	17
66	The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. Experimental Eye Research, 2019, 182, 144-155.	2.6	17
67	Ketamine Does Not Produce Relief of Neuropathic Pain in Mice Lacking the Î²-Common Receptor (CD131). PLoS ONE, 2013, 8, e71326.	2.5	15
68	Activation of the EPOR-Î² common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 632-639.	3.8	14
69	Quantification of small fiber pathology in patients with sarcoidosis and chronic pain using cornea confocal microscopy and skin biopsies. Journal of Pain Research, 2017, Volume 10, 2057-2065.	2.0	13
70	Neurons Are a Primary Driver of Inflammation via Release of HMGB1. Cells, 2021, 10, 2791.	4.1	13
71	Control of inflammation using non-invasive neuromodulation: past, present and promise. International Immunology, 2022, 34, 119-128.	4.0	11
72	The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opinion on Orphan Drugs, 2013, 1, 77-87.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Erythropoietin and Engineered Innate Repair Activators. <i>Methods in Molecular Biology</i> , 2013, 982, 1-11.	0.9	10
74	ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. <i>Molecular Medicine</i> , 2015, 21, 969-978.	4.4	10
75	Targeting the innate repair receptor to treat neuropathy. <i>Pain Reports</i> , 2016, 1, e566.	2.7	9
76	Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. <i>Scientific Reports</i> , 2017, 7, 13012.	3.3	9
77	The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 77-87.	0.8	7
78	A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. <i>Journal of Clinical Medicine</i> , 2020, 9, 2225.	2.4	7
79	Anthropometric Variables Accurately Predict Dual Energy X-Ray Absorptiometric-Derived Body Composition and Can Be Used to Screen for Diabetes. <i>PLoS ONE</i> , 2011, 6, e24017.	2.5	6
80	Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. <i>Cell Transplantation</i> , 2021, 30, 096368972110397.	2.5	5
81	Systemic administration of choline acetyltransferase decreases blood pressure in murine hypertension. <i>Molecular Medicine</i> , 2021, 27, 133.	4.4	5
82	Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. <i>Transplantation</i> , 2020, 104, 2048-2058.	1.0	4
83	Erythropoietin in Spinal Cord Injury. , 2006, , 147-164.		3
84	The erythropoietin-derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 2202-2210.	7.3	2
85	An Engineered Innate Repair Receptor Agonist, ARA 290, Protects Rat Islets from Cytokine-induced Apoptosis. <i>Journal of Diabetes & Metabolism</i> , 2016, 7, .	0.2	1
86	Specific ligand for the innate repair receptor, ARA290, attenuates pulmonary hypertension in an elastase-induced murine model of emphysema. , 2017, , .		1
87	The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 55.	4.1	1
88	Famotidine exerts anti-inflammatory effects via a vagus nerve-dependent mechanism. <i>FASEB Journal</i> , 2022, 36, .	0.5	1
89	Improvement of Metabolic Function after Intra-Portal Allogeneic Islet Transplantation Using Induction Treatment of the Non-Hematopoietic Erythropoietin Analogue Cibinetide in a Mouse Model. <i>Transplantation</i> , 2018, 102, S747-S748.	1.0	0
90	Extrahematopoietic Actions of Erythropoietin. , 2018, , 411-428.		0

#	ARTICLE	IF	CITATIONS
91	Functional and symptomatic burden of small fiber neuropathy in sarcoidosis. , 2017, , .		0
92	Editorial: Erythropoietin and Its Analogues as Therapeutics for Neurological Diseases. Frontiers in Pharmacology, 2022, 13, 841538.	3.5	0